Developing a surgical infection treatment to reduce amputations, healing times and hospital stays for diabetic foot patients

Project Information

XTremedy Medical

Grant agreement ID: 101069625

DOI

10.3030/101069625

Project closed

EC signature date 20 June 2022

Start date 1 July 2022

End date 31 December 2022

Funded under

• European innovation ecosystems

Total cost

No data

EU contribution

€ 75 000,00

Coordinated by

XTREMEDY MEDICAL LIMITED
Ireland

Periodic Reporting for period 1 - XTremedy Medical (Developing a surgical infection treatment to reduce amputations, healing times and hospital stays for diabetic foot patients)

Reporting period: 2022-07-01 to 2022-12-31

Summary of the context and overall objectives of the project

XTremedy Medical are a surgical device company developing treatments for infected wounds, in particular Diabetic Foot Ulcers (DFUs). Infection has now been recognised as a leading cause of wound chronicity - wounds that do not respond to initial treatments.i Infections that spread to deep muscle and bone tissues, are the leading cause of amputations in diabetics. Biofilms, a type of infection often found in wounds, are complex to treat with up to 1000-fold tolerance to antibiotics.ii High concentrations of antibiotics required to treat these infections impairs kidney function and leads to high rates of kidney failure.
XTremedy Medical overcomes limitations with current solutions by treating both surface and subsurface tissues without disrupting tissue structures. XTremedy’s first device – BioBlate, is a non-thermal ablation device using pulsed electric field ablation (PFA) to treat biofilms. PFA is known for its anti-microbial and non-destructive properties.
Incorporating BioBlate technology enables the surgeon to remove all biofilm within the wound without removing excess healthy tissue which impairs healing. Delivering wound margins free of biofilm leads to fewer surgeries and shortened hospital stays

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Commercialisation (regulatory and market access) strategy mapped for BioBlate technology

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Xtremedy have demonstrated that thier PFA device is up to 1000x more effective at removing biofilm/bioburden than the standard of care (saline flush). Using the BioBlate device, the team achieved 6 log reductions in ex-vivo staph epidermis biofilms and 4 log reductions in staph aureus. This is compared to <1 log reduction with the standard of care, a saline flush. These results have been validated in a third party lab.